Therapy Areas: Oncology
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
23 October 2026 - Zai Lab Limited (NASDAQ:ZLAB) (HKEX:9688), a research-based, commercial-stage biopharmaceutical company based in China and the United States, on Friday reported promising initial res...
HUYABIO International reports positive Phase 3 trial results for HBI-8000 and nivolumab combination
23 October 2026 - Biopharmaceutical company HUYABIO International announced on Thursday that oral HBI-8000 in combination with intravenous nivolumab reduced the risk of disease progression or death by...
ImmunoForge to participate in BIO-Europe 2026
23 October 2026 - South Korea-based ImmunoForge Co Ltd, a clinical-stage biopharmaceutical company focused on developing therapies for rare, neuromuscular, metabolic diseases, and targeted oncology, a...
IHI and Bristol Myers Squibb launch initiative to expand cancer clinical trial access
22 October 2026 - The Institute for Healthcare Improvement (IHI) and biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) on Thursday launched a three-year Cancer Collective Action Collaborative ...
Summit Therapeutics and ECOG-ACRIN launch Phase II/III trial collaboration for biliary tract cancer
21 October 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) said on Wednesday that it has partnered with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab in ...
Abbott secures CE Mark for Cologuard Plus in Europe
20 October 2026 - Abbott Laboratories (NYSE: ABT), a global healthcare company, said on Tuesday that Cologuard Plus has received CE Mark approval under the European Union's In Vitro Diagnostic Me...